VitaNova Q1 Loss Widens 166% as Gross Margin Collapses to 9%
VNOV sits 87% above its 52-week low of $1.27 on light trading volume (0.3× avg).
Summary
VitaNova's Q1 revenue tripled but gross margin collapsed to 9%, widening the net loss to $123,101. Material weaknesses in internal controls remain unremediated.
Key Events · Earnings and Guidance · VNOV
-
Revenue Triples on New Food Line
Q1 FY2027 revenue reached $321,576, up 210% from $103,899 a year ago, driven by $234,576 in healthy food product sales.
-
Gross Margin Collapses to 9%
Gross profit fell to $30,521 from $68,781 as the new food line carries only a 3% margin, dragging overall gross margin from 66% to 9%.
-
Net Loss Widens 166%
Net loss increased to $123,101 from $46,301, with operating expenses up 51% to $152,683 due to higher legal and professional fees.
-
Material Weaknesses Reaffirmed
Management confirms ineffective disclosure controls due to no audit committee and insufficient qualified accounting personnel — same weaknesses disclosed in the July 10-K, with no remediation completed.
Analysis · VNOV · Trade & Services
VitaNova's first quarter shows revenue tripling to $321,576, but the new healthy food line carries only a 3% margin, dragging overall gross margin from 66% to 9%. Net loss widened to $123,101 from $46,301. Management reaffirms material weaknesses in internal controls — no audit committee and insufficient accounting personnel — first disclosed in the July 10-K. The company holds $1.6M in cash and says it has 12 months of runway, but the deteriorating unit economics and unresolved governance issues make this a high-risk micro-cap.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNOV was trading at $2.38 on OTC in the Trade & Services sector, with a market capitalization of approximately $19.8M. The 52-week trading range was $1.27 to $45.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.